Christy Richardson, MD
Endocrinology, Diabetes & Metabolism · Bridgeton, MONPI 1548241284
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $46,050 of the $66,459 with a category attached, or 69.3%. Lilly USA, LLC accounts for 77.7% of it on its own, with 25 other manufacturers making up the rest. Reporting peaked in 2019 at $35,970 and has fallen 96.6% since, to $1,215 in 2025. Among endocrinology, diabetes & metabolism clinicians in MO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 193 payments — averaging $344.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$52K
- Boehringer Ingelheim$12K
- Medtronic$626
- Abbott$421
- Sanofi-aventis U.S. LLC$244
- AstraZeneca$191
- plus $1K from 20 others
What the payments were for
- Consulting fees$8,28812%
- Speaking & faculty fees$46,05069%
- Travel & lodging$7,75912%
- Food & beverage$4,3627%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 98 | $51,656 |
| Boehringer Ingelheim | 22 | $12,057 |
| Medtronic(2 entities) | 7 | $626 |
| Abbott | 10 | $421 |
| Sanofi-aventis U.S. LLC | 3 | $244 |
| AstraZeneca | 2 | $191 |
| Novo Nordisk | 9 | $183 |
| Neurocrine Biosciences, Inc. | 2 | $158 |
| Corcept Therapeutics | 5 | $137 |
| Novartis | 6 | $129 |
| Radius Health, Inc. | 3 | $81 |
| Amgen | 3 | $72 |
| Averitas Pharma Inc. | 3 | $71 |
| Dexcom, Inc. | 3 | $63 |
| Sequel Med Tech, LLC | 3 | $55 |
| Bayer | 2 | $54 |
| Amneal Pharmaceuticals LLC | 3 | $49 |
| Recordati_rare_diseases_inc. | 1 | $34 |
| Xeris Pharmaceuticals, Inc. | 1 | $28 |
| Esperion Therapeutics, Inc. | 1 | $28 |
| Ascensia Diabetes Care US Inc. | 1 | $27 |
| Antares Pharma, Inc. | 1 | $21 |
| Mannkind Corporation | 1 | $21 |
| Tandem Diabetes Care, Inc. | 1 | $20 |
| BETA Bionics, Inc. | 1 | $18 |
| RGH Enterprises LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- HUMULIN$24,138
- JARDIANCE$18,328
- LYUMJEV$5,475
- TRULICITY$1,715
- MINIMED 780G$289
- FreeStyle Libre Pro$217
- TOUJEO$216
- FARXIGA$123
- CRENESSITY$123
- SOLIQUA 100/33$112
- Minimed 670G System$102
How this compares
$66,459 in reported general payments places this provider in the 90th percentile of 182 endocrinology, diabetes & metabolism providers in Missouri.
See all endocrinology, diabetes & metabolism providers in Missouri →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 348 | $498,757 |
| TrulicityDulaglutide | 104 | $194,349 |
| MounjaroTirzepatide | 134 | $170,085 |
| Tresiba Flextouch U-200Insulin Degludec | 90 | $93,578 |
| JardianceEmpagliflozin | 75 | $87,958 |
| FarxigaDapagliflozin Propanediol | 63 | $61,787 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 62 | $59,365 |
| Tresiba Flextouch U-100Insulin Degludec | 104 | $53,516 |
| Xigduo XrDapaglifloz Propaned/Metformin | 47 | $46,207 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 24 | $37,624 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 24 | $27,947 |
| Lyumjev Kwikpen U-100Insulin Lispro-Aabc | 29 | $26,492 |
| RybelsusSemaglutide | 22 | $24,956 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 36 | $20,131 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 27 | $15,042 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $183 | $523,713370 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $51,656 | $370,242264 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $12,057 | $115,90599 claims |
| AstraZenecaFarxiga | $191 | $61,78763 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $49 | $4,503363 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 182 endocrinology, diabetes & metabolism providers in Missouri.
Other endocrinology, diabetes & metabolism in Bridgeton
- Anoj GoelBridgeton$58K
- Ralph DudaSpringfield$644K
- Karen Chang-ChenChesterfield$640K
- Alan RaubaJefferson City$594K
- Jerome ThurmanSaint Charles$312K
- Janet McGillSaint Louis$212K
- Megan WoodSt. Louis$207K
- Ralph OiknineChesterfield$144K
- Jonben SvobodaSpringfield$142K
- James BonucchiSpringfield$128K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.